Navigation Links
Anthera Announces Last Patient Enrolled in PEARL-SC Study
Date:10/25/2011

HAYWARD, Calif., Oct. 25, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it has completed enrollment in the Phase 2b PEARL-SC study.  PEARL-SC (A randomized, double-blind Phase 2b study to evaluate the efficacy, safety, and tolerability of blisibimod administration in subjects with systemic lupus erythematosus) is examining the therapeutic benefit of weekly and monthly subcutaneous injections of blisibimod in patients with active and antibody positive systemic lupus erythematosus (SLE).  The targeted number of five hundred and forty (540) patients has been randomized in 11 countries and 72 clinical sites worldwide.

Also, as part of the Company's efforts to improve treatment options for patients with SLE, the Company submitted a protocol amendment to the FDA for the PEARL-SC clinical study that proposes a modification in the primary efficacy SLE response index to require a larger decrease in the SELENA-SLEDAI* clinical assessment score.  The proposed primary endpoint will require patients to demonstrate a greater than or equal to five (>5) point reduction in the SELENA-SLEDAI, a well-recognized clinical assessment of lupus activity.  The remainder of the responder index will remain unchanged with no new BILAG A or two new BILAG B organ domain flares, and less than a 0.3 (<0.3) increase on a three point scale in Physician's Global Assessment.

"As we move forward with the development of blisibimod, we are incorporating feedback from industry experts, physicians, and key opinion leaders regarding the potential for blisibimod to provide incremental benefits to patients with systemic lupus erythematosus compared to currently available therapies and other advanced stage clinical treatments," said Colin Hislop
'/>"/>

SOURCE Anthera Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anthera Pharmaceuticals Announces Notice of Allowance of U.S. Patent Application Covering A-002 Plus Statin Compositions
2. Anthera Pharmaceuticals Reports 2011 Second Quarter Financial Results and Operational Update
3. Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
4. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5. Anthera Pharmaceuticals Reports 2011 First Quarter Financial Results and Operational Update
6. Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis of VISTA-16 Study and Third Safety Review of Varespladib Methyl
7. Anthera Announces Conference Call to Discuss Analytical Method and Timing of Upcoming VISTA-16 Biomarker Analysis
8. Anthera Pharmaceuticals Names Lawrence Rosania as Vice President of Global Regulatory Affairs and Compliance
9. Dr. Peter Thompson Joins Anthera Pharmaceuticals Board of Directors
10. Anthera Pharmaceuticals Selects the Merck BioManufacturing Network as Manufacturing Supplier for A-623, Antheras Investigational Novel Peptibody Agent
11. Anthera Announces Update Call Regarding Vial Problems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... -- UBM Medica US announces that Diagnostic Imaging ... professionals, explored the complex situation regarding measuring the ... The shift from fee-for-service has left radiology at a ... determined in the new payment model . ... who recognized the complexity of the radiologist,s value: ...
(Date:7/28/2014)... July 28, 2014  Array BioPharma Inc. (Nasdaq: ... the fourth quarter and full year of ... to discuss those results on Tuesday, August ... and Michael Carruthers , Chief Financial ... August 12, 2014Time:9:00 a.m. Eastern TimeToll-Free:(800) 708-4540Toll:(847) ...
(Date:7/28/2014)... 28, 2014  A prospective study conducted by ... has validated the performance of VolparaDensity breast ... associated volumetrically assessed breast density measurements to breast ... & Prevention (DOI: 10.1158/1055-9965.EPI-13-1219), the article, "Automated ... widespread breast cancer risk assessment," was authored by ...
Breaking Medicine Technology:Diagnostic Imaging Delves into Measuring the Radiologist's Value 2Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 2Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 3Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 4
... TOULOUSE, France, May 15 Cerenis,Therapeutics SA ... compounds for the treatment of cardiovascular and,metabolic ... a Phase I,clinical trial for CER-002, one ... a peroxisome proliferator-activated receptor (PPAR),delta-specific agonist in ...
... Therapy that, Combined, with Aspirin, Causes Less Bleeding ... and Aspirin, According to a New Report ... Decision Resources, one of the,world,s leading research ... that Daiichi Sankyo/Eli Lilly,s Effient offers,improvement in patient ...
Cached Medicine Technology:Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3
(Date:7/28/2014)... near green spaces deliver babies with significantly higher ... Spaces and Adverse Pregnancy Outcomes" published in the ... A team of researchers from Israel and Spain, ... nearly 40,000 single live births from a registry ... the impact of green surroundings during pregnancy and ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Drorit Silverman, ... unveiled new plans to raise investment capital through her ... fitness concept in the United States. , According to ... of 24/7 fitness centers provide a great window of ... rapidly expanding space. In addition to this, Silverman looks ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Qualis ... and care management organizations, has published a complimentary, ... approach to engaging patients and families in infection ... at multiple hospitals, the toolkit provides a step-by-step ... with patients and their families early in a ...
(Date:7/28/2014)... (HealthDay News) -- A common inflammatory muscle disorder ... may increase the risk for heart attack and ... study found that patients with polymyalgia rheumatica are ... that affect the blood vessels. Doctors should carefully ... polymyalgia rheumatica to reduce their risk for complications, ...
(Date:7/28/2014)... (SMU) Smart phones and mobile devices are on ... health ("mHealth") apps capable of providing everything from cardiac ... broaden access to medical treatment and control costs, several ... England Journal of Medicine (NEJM) report that more ... Administration (FDA) to ensure consumer confidence and safety. Out ...
Breaking Medicine News(10 mins):Health News:Pro Bodybuilder Drorit Silverman Confirms Plans to Raise Money for Investment in the Popular 24/7 Fitness Concept 2Health News:Patient Engagement in Hospital Infection Control: Online Toolkit Provides a New Solution 2Health News:Inflammatory Muscle Disorder May Raise Risk for Heart Attack, Stroke 2Health News:Booming mobile health app market needs more FDA oversight for consumer safety, confidence 2
... Corresponding Journal of Nutrition supplement urges health professionals to ... to be published in the June issue of the ... and the general public to stop demonizing high fructose ... rethink the myths about high fructose corn syrup,s impact ...
... NAS to Store Public Database of Genomic and Trait Data ... Isilon(R) Systems (Nasdaq: ISLN ), the ... Personal Genome Project (PGP) has deployed Isilon ... for an unprecedented research project aimed at transforming the use ...
... Keeping Up on Developments in the Long term Care Insurance ... interest in long term care insurance need no longer dig ... pros do: have the information come to them, in bits ... secrets," says Jonas Roeser, Senior Vice President of Marketing & ...
... on lung cancer and mesothelioma specialists into one of ... asbestos-related diseases. Our searchable, easy-to-use database contains doctor profiles ... it easy for residents of California or New York, ... in their area. , ...
... medical malpractice challenge by introducing low tech solution ... introduces standardized shift reporting and note taking to ... to day tasks.RNReport Card is more efficient by ... It fits conveniently in the pocket of your ...
... Packard Children,s Hospital and the Stanford University School of ... deadly and mysterious bowel disease that strikes medically fragile ... understanding of the disease and its medical management, and ... major killer of children and young adults. , The ...
Cached Medicine News:Health News:Experts Lay to Rest Long-Held Misconceptions About High Fructose Corn Syrup at ILSI-USDA Workshop 2Health News:Experts Lay to Rest Long-Held Misconceptions About High Fructose Corn Syrup at ILSI-USDA Workshop 3Health News:The Personal Genome Project Deploys Isilon IQ Storage to Transform Genomic Research 2Health News:The Personal Genome Project Deploys Isilon IQ Storage to Transform Genomic Research 3Health News:Long Term Care Alerting Methods Revealed by Industry Leaders 2Health News:MesotheliomaHelp.net Announces Expanded Information on Lung Cancer and Mesothelioma Specialists 2Health News:MesotheliomaHelp.net Announces Expanded Information on Lung Cancer and Mesothelioma Specialists 3Health News:RN Sisters Bring Low-Tech Innovations to New Nurses and Nursing Students 2Health News:Packard/Stanford study suggests two causes for bowel disease in infants 2Health News:Packard/Stanford study suggests two causes for bowel disease in infants 3
... Finn Revision Knee System ... distal femoral replacement options. The ... Finn Rotating Hinge Knee, promotes ... function and is designed for ...
The Advance stemmed medial-pivot knee is a revision knee that provides unique and competitive features....
... The NexGen Legacy LCCK Femoral Component ... additional prosthetic stabilization due to inadequate ... and require augmentation and/or stem extensions ... NexGen LCCK is available with a ...
The Duracon system provides superb articular conformity throughout the range of motion, reducing contact stresses generally associated with wear....
Medicine Products: